In an effort to obtain the flexibility and ease of performance of a rapid, serological test for detection of cytomegalovirus antibody, the indirect hemagglutination (IHA) technique was investigated by using a microserological system. Antigens were prepared from tissue cultures of infected human fibroblasts. Serological methods available for diagnosing cytomegalovirus (CMV) infection have been limited in their usefulness. CMV complement fixation (CF) tests with sera from congenitally infected infants may remain negative in the presence of high titers of neutralizing antibody and despite continued virus excretion (4, 9). Also, with the CF test there are cross-reactions with herpesvirus. Neutralization tests have been found to be relatively strain-specific and require a lengthy incubation time before results can be obtained.
In an effort to obtain the flexibility and ease of performance of a rapid, serological test for detection of cytomegalovirus antibody, the indirect hemagglutination (IHA) technique was investigated by using a microserological system. Antigens were prepared from tissue cultures of infected human fibroblasts. The specificity of the cytomegalovirus antibody response detected by the IHA test correlated well with the standard neutralization test. The IHA method was more sensitive than the complement fixation test in detecting antibody in congenitally infected newborns. There appeared to be some heterologous antibody response with Herpesvirus hominis or varicella virus infections. The IHA test pattern was found to be very stable, with excellent persistence of agglutination.
Serological methods available for diagnosing cytomegalovirus (CMV) infection have been limited in their usefulness. CMV complement fixation (CF) tests with sera from congenitally infected infants may remain negative in the presence of high titers of neutralizing antibody and despite continued virus excretion (4, 9) . Also, with the CF test there are cross-reactions with herpesvirus. Neutralization tests have been found to be relatively strain-specific and require a lengthy incubation time before results can be obtained.
The present report describes the development of and our experience with a rapid, micro indirect hemagglutination (IHA) test for detecting CMV antibody.
MATERIALS AND METHODS
Virus strains. The CMV AD-169 strain (passage 351), supplied by Wallace P. Rowe, National Institutes of Health, was used for the neutralization tests and for the production of viral antigens used in the IHA method. Another strain, P.N. (passage 3), was isolated in our laboratory from an infant with congenital cytomegalic inclusion disease and was also used as a seed virus in the neutralization test (1).
The Herpesvirus hominis strains VR2 (type I) and M.S. (type II) were used for the microneutralization test. These virus strains were obtained from Andre J. Nahmias, Emory University, Atlanta, Ga., at passage level 25 and carried an additional 10 passages in our laboratory.
CF test. The CMV CF antigen (AD-169 strain) and the herpes CF antigen (McIntyre strain), both cell pack antigens, were prepared by Gabriel A.
Castellano, under contract at Microbiological Associates, Bethesda, Md. The methods used for the preparation of these antigens have been reported previously (7) . The CMV and herpes CF tests were performed by utilizing the microtechnique (6 Antigen production for the CMV IHA test. The MA-184 cell cultures were grown to confluency in 32-oz (ca-900 ml) prescription-type culture flasks. After removal of growth medium, the cell cultures were inoculated with 1 ml of AD-169 CMV with a titer of 10" TCIDso per ml. Virus absorption was allowed to occur for 30 min at room temperature, and then maintenance medium (30 ml per bottle) was added and the bottles were incubated at 37 C. Cultures were observed until almost complete cytopathic effect was obtained which occurred usually within 12 to 14 days. Cells were then scraped from the bottle with a rubber spatula, and the suspension was repetitively frozen at -90 C and thawed three times. After the third thaw, cellular debris was removed by centrifugation at 600 X g for 10 min at 4 C, and the supernatant fluid was used as the antigen preparation. Control antigens were prepared similarly from uninoculated tissue cultures.
iHA test. Sheep erythrocytes (3% suspension) were tanned and sensitized as previously described (3).
Briefly, tannic acid (C76H52045) diluted 1:80,000 in PBS was used to tan the red cells. Suspension of cells were then sensitized with a previously determined dilution of antigen in saline (pH 6.4).
The dilution of antigen-sensitized cells used in the test was determined by chessboard titration by using twofold dilutions of antigen against an immune serum previously tested by CF and neutralization tests. Antigens prepared as described above were satisfactory when employed at a dilution of 1: 8. This dilution was selected since further increase in antigen dilution did not appreciably change the titer of the control immune serum. Control antigens were used at the same dilution as employed in the test.
Testing was performed with the micromethod utilizing spiral loops and V-bottom, soft, plastic plates (Cooke Engineering Co., Alexandria, Va.) as previously described (3, 6) .
Standard negative and positive antisera were included in all tests. Controls consisted of (i) serum diluent with sensitized red cells, (ii) serum diluent with antigen-free tanned red cells, (iii) 1: 8 dilution of serum with tanned cells. Titers were taken as the highest dilution of serum which gave a 3+ agglutination on a scale of 0 to 4+. A control antigen from each lot of test antigen produced was prescreened for any nonspecific reactions with a series of human sera.
RESULTS
The MA-184 cell cultures proved to be the best tissue for antigen production; however, tissue has also been used with some success. Cell pack antigens were also tested but did not demonstrate sufficient antigen.
Both An additional study of sensitivity and specificity was done with serum specimens from three congenitally infected children (Table 1) . Neutralizing antibody titers were determined by using the AD-169 strain and the virus from patient 1 (strain P.N.).
At the ages shown, all patients developed neutralizing antibody to AD-169 but only patient 1 developed antibody to strain P.N., his own virus strain. CF antibody was assayed for all serum samples. The results show that patients 1 and 3 had detectable CF antibody, but patient 2 had no CF antibody until 1 year of age despite continued virus excretion. With the IHA test, all three patients had antibody at a titer of 128. Herpes CF antibody was detected in the serum of patient 3, but the other two patients were negative, indicating that the IHA results were not caused by a heterologous reaction with the closely related herpesvirus antigen. Human sera with and without CF varicella-zoster and H. hominis and body to CMV as tested by CF or r were used to detect possible cross-r these viruses. No cross-reactions wer Rabbit CMV pre-and postimmu were obtained from Lidia M. Marl Cancer Institute. Rabbits were imn the AD-169 strain, and the hyperir had a titer of 128 with the plaque r With the IHA CMV test, the prei specimen was negative and the postii specimen had a titer of 64. 
